Alnylam Pharmaceuticals | ALNY - Operating Expenses

Stock Price
351.80
Daily Change
12.69 3.74%
Monthly
-11.57%
Yearly
29.82%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $881.04M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Arrowhead Research USD 212.37M 19.05M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Moderna USD 1.28B 232M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.77B 401M Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Takeda JPY 1.02T 400.98B Dec/2025
Tectonic Therapeutic USD 21.89M 440K Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025
Xencor USD 68.52M 8.26M Sep/2025